NEW YORK (GenomeWeb) – Talis Biomedical said today that CARB-X has awarded it $4.4 million to further its point-of-care technology for pathogen identification and antibiotic-susceptibility testing.
The award will go toward development of Talis Bio's rapid CLIA-waived molecular diagnostic test for detecting chlamydia and gonorrhea directly from a patient's sample in no more than 20 minutes, as well as a rapid phenotypic antibiotic susceptibility test for gonorrhea.